BLAINJECTIONINJECTABLE
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
REZVOGLAR (insulin glargine-aglr) by Eli Lilly and Company. Approved for type 2 diabetes mellitus, type 1 diabetes mellitus. First approved in 2021.
Drug data last refreshed 20h ago
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications (2)
Worked on REZVOGLAR at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.